Finding Mentors and Forging Connections in the Brain Cancer Field

Commentary
Video

The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.

Yoshie Umemura, MD, spoke with CancerNetwork® about advice she would offer to aspiring neuro-oncologists who aim to progress in the brain cancer field. Specifically, she focused on what to look out for in terms of mentorship.

Above all else, Umemura, the chief medical officer of the Ivy Brain Tumor Center, division chief of Neuro-Oncology, and the William and Joan Shapiro chair of Neuro-Oncology at Barrow Neurological Institute, emphasized having the confidence to ask others outside of one’s institution to form new connections and mentorships. Additionally, she described how those in the field can pay it forward by being open to mentoring other aspiring neuro-oncologists.

Transcript:

I have spoken with some people who felt they lacked a mentor. The common things I hear are, “Oh, there wasn’t anyone like that at my institution.” The best advice I can give them is to just ask. When you are at a conference and you meet someone, you think you might click with, you’re intrigued about, or you’re impressed with, you can shoot an email and ask them if they would be open to chatting with you about a question or mentoring you. I have multiple mentors outside of my institution, and I have been very fortunate to have them. At the same time, I’ve asked [them]. The worst thing that’s going to happen is they [may be] too busy, right? No one is going to make you feel terrible about yourself just because you showed an initiative to get a mentor. [You should also] pay it forward. Always be open to mentoring others; that’s the only way to move forward. Don’t limit yourself to just what’s around you. It [speaks] to the collaborative aspect and how to operate as an outsider. You’re not an outsider as long as you make the connection; you can just wedge yourself in. Just ask.

Recent Videos
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Ruxolitinib, currently approved for as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.